File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Interleukin-5 messenger RNA expression in peripheral blood CD4 + cells in asthma

TitleInterleukin-5 messenger RNA expression in peripheral blood CD4 + cells in asthma
Authors
Keywordsasthma
corticosteroids
Cytokines
eosinophil cationic protein
eosinophils
IL-5
T lymphocytes
Issue Date1996
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jaci
Citation
Journal Of Allergy And Clinical Immunology, 1996, v. 97 n. 6, p. 1320-1328 How to Cite?
AbstractBackground: IL-5 has been implicated in the pathogenesis of asthma through its regulatory role on eosinophil survival, proliferation, and effector function. Objective: The study was designed to investigate the relationships between IL-5 messenger RNA expression in circulating CD4 + cells and serum concentrations of eosinophil cationic protein (ECP), a marker of eosinophil activation and disease activity in asthma. Methods: IL-5 gene expression was assessed semiquantitatively in ex-vivo stimulate CD4 + cells by reverse transcription-polymerase chain reaction and serum ECP concentration measured from venous blood samples collected from patients with acute severe asthma before the commencement of systemic steroid therapy (day 1) and on day 7 and from patients with stable and healthy volunteers. Results IL-5 gene expression was significantly higher in patients with acute asthma before steroid treatment than in those with stable disease and healthy subjects (p<0.0001). Similar results were obtained with serum ECP levels; levels in patients with acute asthma were highest (20.30 ± 5.31 μg/L), followed by levels in patients with stable asthma (2.76 ± 0.65 2mg/L) and levels in normal control subjects (1.37 ± 0.06 μg/L; p < 0.01 for all comparisons). Significant falls in both IL-5 expression and serum ECP level were seen on day 7 (p < 0.001) and coincided with a significant improvement in peak expiratory flow (p < 0001). Significant correlations were observed between IL-5 expressions and ECP level (p = 0.39, p <0.01), IL-5 expression and peak expiratory flow (p = -0.55, p < 0.0002), and peak expiratory flow and ECP level (p = -0.32, p < 0.04). Conclusions: Our data therefore support an important regulatory role of IL-5 on eosinophil function in human asthma in vivo.
Persistent Identifierhttp://hdl.handle.net/10722/162155
ISSN
2015 Impact Factor: 12.485
2015 SCImago Journal Rankings: 5.513
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, CKWen_HK
dc.contributor.authorHo, ASSen_HK
dc.contributor.authorChan, CHSen_HK
dc.contributor.authorTang, Jen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2012-09-05T05:17:42Z-
dc.date.available2012-09-05T05:17:42Z-
dc.date.issued1996en_HK
dc.identifier.citationJournal Of Allergy And Clinical Immunology, 1996, v. 97 n. 6, p. 1320-1328en_HK
dc.identifier.issn0091-6749en_HK
dc.identifier.urihttp://hdl.handle.net/10722/162155-
dc.description.abstractBackground: IL-5 has been implicated in the pathogenesis of asthma through its regulatory role on eosinophil survival, proliferation, and effector function. Objective: The study was designed to investigate the relationships between IL-5 messenger RNA expression in circulating CD4 + cells and serum concentrations of eosinophil cationic protein (ECP), a marker of eosinophil activation and disease activity in asthma. Methods: IL-5 gene expression was assessed semiquantitatively in ex-vivo stimulate CD4 + cells by reverse transcription-polymerase chain reaction and serum ECP concentration measured from venous blood samples collected from patients with acute severe asthma before the commencement of systemic steroid therapy (day 1) and on day 7 and from patients with stable and healthy volunteers. Results IL-5 gene expression was significantly higher in patients with acute asthma before steroid treatment than in those with stable disease and healthy subjects (p<0.0001). Similar results were obtained with serum ECP levels; levels in patients with acute asthma were highest (20.30 ± 5.31 μg/L), followed by levels in patients with stable asthma (2.76 ± 0.65 2mg/L) and levels in normal control subjects (1.37 ± 0.06 μg/L; p < 0.01 for all comparisons). Significant falls in both IL-5 expression and serum ECP level were seen on day 7 (p < 0.001) and coincided with a significant improvement in peak expiratory flow (p < 0001). Significant correlations were observed between IL-5 expressions and ECP level (p = 0.39, p <0.01), IL-5 expression and peak expiratory flow (p = -0.55, p < 0.0002), and peak expiratory flow and ECP level (p = -0.32, p < 0.04). Conclusions: Our data therefore support an important regulatory role of IL-5 on eosinophil function in human asthma in vivo.en_HK
dc.languageengen_US
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jacien_HK
dc.relation.ispartofJournal of Allergy and Clinical Immunologyen_HK
dc.subjectasthmaen_HK
dc.subjectcorticosteroidsen_HK
dc.subjectCytokinesen_HK
dc.subjecteosinophil cationic proteinen_HK
dc.subjecteosinophilsen_HK
dc.subjectIL-5en_HK
dc.subjectT lymphocytesen_HK
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAsthma - Metabolismen_US
dc.subject.meshBase Sequenceen_US
dc.subject.meshBlood Proteins - Metabolismen_US
dc.subject.meshCd4-Positive T-Lymphocytes - Metabolismen_US
dc.subject.meshCells, Cultureden_US
dc.subject.meshCytokines - Geneticsen_US
dc.subject.meshDna Primers - Chemistryen_US
dc.subject.meshEosinophil Granule Proteinsen_US
dc.subject.meshGene Expressionen_US
dc.subject.meshHumansen_US
dc.subject.meshInterleukin-5 - Geneticsen_US
dc.subject.meshMolecular Sequence Dataen_US
dc.subject.meshRna, Messenger - Geneticsen_US
dc.subject.meshRibonucleasesen_US
dc.titleInterleukin-5 messenger RNA expression in peripheral blood CD4 + cells in asthmaen_HK
dc.typeArticleen_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0091-6749(96)70201-4en_HK
dc.identifier.pmid8648029-
dc.identifier.scopuseid_2-s2.0-0030003887en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0030003887&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume97en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1320en_HK
dc.identifier.epage1328en_HK
dc.identifier.isiWOS:A1996VD60700021-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLai, CKW=7403086390en_HK
dc.identifier.scopusauthoridHo, ASS=7402675199en_HK
dc.identifier.scopusauthoridChan, CHS=16169208100en_HK
dc.identifier.scopusauthoridTang, J=8501399000en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats